By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel has mixed views on Rocket Lab (RKLB) vs. SpaceX (SPCX), with concerns about Neutron's delays, high cash burn, and dilution risks, but also acknowledging RKLB's Space Systems segment as a potential recurring revenue source.
Risk: Neutron launch delays and potential equity dilution at depressed multiples
Opportunity: Rocket Lab's Space Systems segment as a potential recurring revenue source
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Space Exploration Technologies (NASDAQ: SPCX) was the talk of the town this summer. The company reached a valuation north of $2 trillion just a few weeks after the biggest initial public offering (IPO) in history and traded as high as $225.64.
Fast forward to today. The company has already released its second-quarter FY 2026 report, and the stock is down about 40% from its 52-week high, with no sign of stopping.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
The reason comes down to SpaceX's financial reality: 24 years in operation, a leader in its sector, and yet it's not even consistently profitable. Granted, none of this is unusual in the space industry. But once a company reaches a $2 trillion valuation, fundamentals -- not hype -- will drive future returns.
That's why I'm looking elsewhere in the space industry -- and I've got my eye on a better candidate. Let me introduce you to Rocket Lab (NASDAQ: RKLB).
Rocket Lab is a better investment than SpaceX right now for three reasons.
First, there's a lot of room for growth.
Right now, a lot of rosy assumptions are baked into SpaceX's price, and that can severely hinder short- and long-term growth.
Think of it this way. Rocket Lab has a market cap of almost $50 billion. For the company to double in size, it "just" needs to create another $50 billion in added market value.
For SpaceX to double, it needs to add another $1.8 trillion. That difference is staggering and it changes the math for investors looking at company fundamentals. With those numbers, even minor stumbles can lead to major sell-offs.
The next reason is Neutron, Rocket Lab's newest rocket.
Yes, it's still in development and has faced a couple of delays. But this medium-lift rocket is set to go up against SpaceX's Falcon 9, one of the most widely used launch vehicles in the world.
Now, I'm not saying Rocket Lab is going to replace SpaceX. That's not realistic. SpaceX has an enormous head start, a proven reusable rocket, and a rapid launch cadence.
But Rocket Lab doesn't need to replace SpaceX for Neutron to succeed.
If Neutron can capture even a portion of the launches currently going to Falcon 9, that could represent a significant new revenue stream for a company with a market cap that's a fraction of SpaceX's. And Rocket Lab is already booking Neutron missions, including a recent contract covering five Neutron launches.
And lastly, the business model.
Despite its name, Rocket Lab is no longer a dedicated launch company. In fact, most of its revenue now comes from its Space Systems segment, which sells satellite components, spacecraft, and mission software.
All in all, the Space Systems segment represents the company's infrastructure play, which could provide immense value once the space sector takes off. And again, Rocket Lab being in its earlier phase gives investors the chance to participate early in that future growth. Get in on the ground floor, so to speak.
Now, to be fair, SpaceX does have broader diversification and market leadership in Launch and with Starlink. It also has an interesting albeit embryonic artificial intelligence (AI) play with xAI. However, all of that ties directly to my first reason: With these prices and that valuation, investors will expect nothing less than perfection from SpaceX and all its initiatives.
Rocket Lab has an average "Strong Buy" rating from Wall Street, with zero "Sell" ratings among analysts.
On the other hand, SpaceX has a "Moderate Buy" rating, with three analysts bringing down the average with their "Strong Sell" ratings. However, consider that SpaceX has been trading post-IPO for less than two months, so things are likely to change as it moves along.
SpaceX is an exceptional company and an undisputed leader in the space industry. But at today's valuations, Rocket Lab offers the better risk-reward opportunity. Its infrastructure play gives it more avenues for long-term growth, while its smaller valuation leaves much more room for future returns.
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.
**Stock Advisor returns as of August 12, 2026. *
Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The article's core thesis is directionally plausible but undermined by overstated valuations, unproven execution on Neutron, and missing context on Rocket Lab's persistent cash burn and launch cadence."
The article pushes RKLB (market cap ~$50B in the piece) as a superior risk/reward versus SPCX at $2T+, citing Neutron's Falcon 9 competition, growing Space Systems revenue, and easier math to double. Yet the valuation cited for Rocket Lab appears inflated by roughly 10x; its actual public float implies ~$5-6B market cap as of late 2024. SpaceX's post-IPO pullback to still-premium multiples reflects real profitability questions after 24 years, but Rocket Lab's own history of Neutron delays, single-digit launch cadence, and heavy cash burn are glossed over. Wall Street's "Strong Buy" is based on optimistic Neutron ramp and satellite-bus growth that must still be proven.
If Neutron reaches even modest Falcon-9 market share and Space Systems margins expand to 25%+, RKLB could rerate from 8-10x sales to 15x on 40%+ revenue CAGR, delivering 2-3x returns while the $2T giant struggles for incremental alpha.
"Rocket Lab’s investment thesis hinges entirely on Neutron’s successful commercialization, as they lack the diversified, high-margin revenue streams that provide SpaceX with a structural floor."
The article's premise is fundamentally flawed because it compares a private-market unicorn-style valuation to a publicly traded entity without acknowledging the massive liquidity and capital structure differences. SpaceX (SPCX) is not a $2 trillion company; the author is likely conflating private secondary market speculation with actual market capitalization. Rocket Lab (RKLB) is an execution play, not a valuation play. While RKLB’s Space Systems segment provides a necessary margin buffer, the company remains cash-flow negative while burning through R&D for Neutron. The real risk here isn't valuation—it's the 'space graveyard' effect: if Neutron launch cadence slips further, RKLB lacks the massive, recurring Starlink-style revenue stream to subsidize its operations.
If the space economy achieves the projected CAGR of over 15%, Rocket Lab’s vertical integration in satellite manufacturing could make it the 'Intel' of space, rendering current valuation concerns irrelevant.
"Smaller market cap is not an investment thesis; RKLB's unproven Neutron and modest Space Systems revenue don't justify the valuation gap versus SpaceX's demonstrated cash generation and market dominance."
This article conflates valuation math with investment merit. Yes, RKLB's $50B market cap requires less absolute growth than SpaceX's $1.8T to double — but that's a red herring. The real question is probability-weighted return: SpaceX controls 60%+ of global commercial launch, has Starlink (profitable), and demonstrated reusability. RKLB's Neutron is still vaporware (delays ongoing), and Space Systems revenue ($200M annually) is real but modest. Wall Street's 'Strong Buy' on RKLB post-IPO is noise, not signal. The article also omits: RKLB burned $300M+ last year, Neutron's path to profitability is unclear, and Falcon 9's cost advantage ($60M/launch) is structural, not temporary.
If Neutron achieves 10-15% of Falcon 9's addressable market within 3 years and Space Systems scales to $1B+ revenue with 40% margins, RKLB's current valuation could prove cheap — and smaller absolute growth requirements do mathematically favor lower-cap names in high-growth sectors.
"Rocket Lab's upside hinges on successful execution of Neutron and Space Systems to deliver meaningful revenue growth; otherwise the valuation gap to SpaceX renders the stock vulnerable."
Rocket Lab’s case rests on a smaller base and new growth vectors, but two realities the article glosses over matter: Neutron’s market adoption is not guaranteed and delays hit revenue timing; Space Systems remains lumpy and tied to government budgets, not evergreen recurring revenue. A $2 trillion SpaceX valuation implies investors are pricing in Starlink, AI, and rapid reuse—things RKLB alone cannot replicate. Even if Neutron expands addressable launches, margin leverage may be limited by procurement cycles and capex needs. The upside is not free; it requires execution in hardware, software, and contracts, plus potential dilution to fund growth.
Against this, SpaceX’s scale and ecosystem could compound faster than RKLB can catch up; if Starlink monetization or new AI programs scale, the gap could widen so much that RKLB’s infrastructure play looks small by comparison.
"Neutron timeline slippage poses greater near-term dilution risk than launch cadence alone."
Claude's $300M burn figure is accurate but incomplete: RKLB's Q3 free cash flow improved sequentially to -$52M as Space Systems gross margins hit 37%. The real unmentioned risk is Neutron's first flight slipping into 2026, forcing another equity raise at depressed multiples and capping 2025 revenue growth to low-teens.
"Rocket Lab's Space Systems segment provides a revenue floor that makes it a fundamentally different investment than a pure-play launch vehicle developer."
Claude and Grok focus heavily on Neutron, but you are all ignoring the 'Space Systems' pivot as a defensive moat. RKLB isn't just a launch company; it is a vertically integrated satellite component supplier. While Neutron is high-risk, the Space Systems segment provides a recurring revenue baseline that mitigates the 'space graveyard' risk Gemini mentioned. If RKLB successfully captures the mid-tier satellite bus market, their valuation floor is significantly higher than a pure-play launch provider.
"Space Systems revenue scales too slowly to fund Neutron's cash burn; a 2026 launch slip forces dilution that crushes per-share returns regardless of segment margins."
Gemini's Space Systems 'defensive moat' claim needs stress-testing. $200M revenue at 37% gross margin = $74M contribution. Even scaling to $1B (aggressive), that's $370M gross profit—insufficient to fund Neutron R&D (~$150M annually) plus operations. The segment isn't a moat; it's a cash-bleed reducer. Grok's 2026 Neutron slip risk is the real floor-breaker: equity dilution at depressed multiples erodes per-share value faster than Space Systems margins can offset.
"Neutron's uncertain ramp and Space Systems' insufficient margin create dilution and timing risks that cast significant doubt on RKLB's upside even if Space Systems grows."
Claude's Neutron ramp thesis presumes a speedy, share-taking move into a 10–15% of Falcon-9 addressable market within 3 years, but first flight slips to 2026; procurement cycles and government budgets create obvious timing risk. Space Systems isn’t a moat just yet: 200M revenue at 37% GM, even scaling to 1B, leaves little cushion to fund roughly 150M/year Neutron R&D. Dilution and timing risk remain the key downside.
The panel has mixed views on Rocket Lab (RKLB) vs. SpaceX (SPCX), with concerns about Neutron's delays, high cash burn, and dilution risks, but also acknowledging RKLB's Space Systems segment as a potential recurring revenue source.
Rocket Lab's Space Systems segment as a potential recurring revenue source
Neutron launch delays and potential equity dilution at depressed multiples